Table 4 Summary estimates of the hazard ratio (HR) for the associations of high Ki-67 expression with overall survival (OS) of subtypes of lymphoma
| Â | Heterogeneity | |||||
|---|---|---|---|---|---|---|
Subtypes of lymphoma | Number of studies | Number of patients | Pooled HR(95% CI) | P value | I2(%) | P value |
HL | 2 | 162 | 1.511(0.524-4.358) | 0.445 | 64.7% | 0.092 |
NHL | 22 | 3708 | 1.777(1.463-2.159) | 0.000 | 74.3% | 0.000 |
DLBCL (total) | 11 | 2588 | 1.457(1.123-1.891) | 0.005 | 67.7% | 0.000 |
DLBCL (with rituximab) | 5 | 753 | 1.495(1.084-2.062) | 0.014 | 52.3% | 0.078 |
DLBCL (without rituximab) | 9 | 1835 | 1.456(0.951-2.23) | 0,084 | 74.8% | 0.000 |
MCL (total) | 7 | 904 | 2.48(1.61-3.81) | 0.000 | 85.6% | 0.000 |
MCL (with rituximab) | 3 | 581 | 1.981(1.099-3.569) | 0.023 | 87.4% | 0.000 |
MCL (without rituximab) | 3 | 243 | 3.123(2.049-4.76) | 0.000 | 21.8% | 0.278 |
NK/TL | 2 | 93 | 4.766(1.917-11.849) | 0.001 | 0% | 0.853 |